R&D | January 02, 2025
Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
elanese now offers Zytel Resin, Hytrel TPC, Crastin PBT and Micromax Electronic Inks and Paste following its 2022 acquisition of the majority of the Mobility & Materials (M&M) business from DuPont
Ayurveda OPD will be established in 10 ECHS Polyclinic/Dispensaries in various regions of India to cover all ECHS members on a voluntary basis
Investment with representation on the Board of Directors and technical know-how
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Subscribe To Our Newsletter & Stay Updated
